| TILs | Tumor-infiltrating lymphocytes |
| MHC | Major histocompatibility complex |
| CTL | Cytotoxic T lymphocytes |
| NK | Natural killer |
| PD-1 | Programmed cell death-protein 1 |
| CRLA-4 | CTL-associated protein 4 |
| PD-L1 | Programmed cell death-ligand 1 |
| MMR | Mismatch repair |
| IHC | Immunohistochemistry |
| PCR | Polymerase chain reaction |
| NGS | Next-generation sequencing |
| TMB | Tumor mutational burden |
| CD | Companion diagnostic |
| MSI | Microsatellite instability |
| NSCLC | Non-small cell lung cancer |
| TPS | Tumor proportion score |
| CPS | Combined positive score |
| EGFR | Epidermal growth factor receptor |
| TKIs | Tyrosine kinase inhibitors |
| LAG-3 | Lymphocyte activation gene-3 |
| ECP | Eosinophil cationic protein |
| CRC | Colorectal cancer |
| MSI-H | Microsatellite instability high |
| FDA | Food and Drug Administration |
| GC | Gastric cancer |
| OS | Overall survival |
| DFS | Disease-free survival |
| MSS | Microsatellite stable |
| HNSCC | Squamous-cell carcinoma of the head and neck |
| ORR | Objective response rate |
| HPV | Human papillomavirus |
| UC | Urothelial carcinoma |
| POLE | polymerase-ε |
| TCGA | The Cancer Genome Atlas |
| TNBC | Triple-negative breast cancer |
| ER | Estrogen receptor |